Akero Therapeutics Q2 EPS $(0.86) Beats $(0.93) Estimate

Akero Therapeutics (NASDAQ: AKRO) reported quarterly losses of $(0.86) per share which beat the analyst consensus estimate of $(0.93) by 7.53 percent. This is a 6.17 percent decrease over losses of $(0.81) per share from the same period last year.